Natco Pharma Ltd. Shifts to Bullish Momentum Amid Technical Upgrades

Technical Momentum and Indicator Analysis

Recent technical assessments reveal that Natco Pharma's weekly MACD has turned bullish, indicating increasing upward momentum in the medium term. The monthly MACD remains mildly bullish, suggesting that while the longer-term trend is positive, it is yet to accelerate decisively. This is complemented by the daily moving averages, which have shifted to a bullish alignment, with the current price of ₹1,036.95 comfortably above key averages, reinforcing the short-term upward trajectory.

However, the weekly Relative Strength Index (RSI) presents a contrasting view, remaining bearish. This divergence suggests that despite the price gains, the stock may be experiencing some short-term overbought conditions or profit-taking pressures. Conversely, the monthly RSI is bullish, indicating that the longer-term momentum remains intact and supportive of further gains.

Bollinger Bands on both weekly and monthly charts are bullish, reflecting expanding volatility with price action trending towards the upper band. This typically signals strong buying interest and potential continuation of the upward move. The KST (Know Sure Thing) indicator shows a bullish signal on the weekly timeframe but remains bearish monthly, highlighting a nuanced momentum picture that investors should monitor closely.

Volume-based indicators such as On-Balance Volume (OBV) show no clear trend on the weekly scale but are bullish monthly, suggesting accumulation over the longer term despite some short-term volume fluctuations. Dow Theory assessments align with this, indicating mild bullishness on both weekly and monthly frames, reinforcing the overall positive technical outlook.

Price Performance and Market Context

Natco Pharma's current price of ₹1,036.95 is approaching its 52-week high of ₹1,059.60, having risen from a low of ₹660.05 over the past year. The stock recorded a day change of +3.47% on 11 Mar 2026, with intraday highs touching ₹1,051.20 and lows at ₹1,014.00, reflecting strong intraday buying interest.

Comparatively, Natco Pharma has outperformed the Sensex across multiple time horizons. Over the past week, the stock surged 8.42% while the Sensex declined 2.53%. Over one month, Natco Pharma gained 22.47% against a 7.20% drop in the benchmark. Year-to-date returns stand at 14.76% for the stock versus an 8.23% decline for the Sensex. Even on a one-year basis, Natco Pharma delivered a robust 27.76% return compared to the Sensex’s 5.52% gain.

Longer-term performance remains mixed; the stock has appreciated 86.92% over three years, outperforming the Sensex’s 32.25%, but over five years, it lagged with a 25.59% gain against the Sensex’s 52.51%. Over a decade, the stock’s 113.36% return trails the Sensex’s 217.61%, indicating that while recent momentum is strong, historical gains have been more modest.

Mojo Score Upgrade and Market Capitalisation Insights

On 10 Mar 2026, Natco Pharma’s Mojo Grade was upgraded from Sell to Hold, reflecting improved technical and fundamental conditions. The current Mojo Score stands at 64.0, signalling a moderate buy sentiment but with caution advised. The Market Cap Grade remains at 3, indicating a mid-tier capitalisation status within the Pharmaceuticals & Biotechnology sector.

This upgrade is significant as it marks a shift in analyst sentiment, driven by the stock’s recent price momentum and technical indicator improvements. The Hold rating suggests that while the stock is no longer a sell candidate, investors should monitor developments closely before committing to a stronger buy position.

Sector and Industry Positioning

Natco Pharma operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and evolving market dynamics. The sector has seen mixed performance recently, with some companies benefiting from increased demand for healthcare products and others facing headwinds from pricing pressures and competition.

Within this context, Natco Pharma’s technical turnaround is noteworthy. The bullish signals across multiple timeframes and indicators suggest that the company is gaining investor favour, potentially due to positive developments in its product pipeline, regulatory approvals, or strategic partnerships. However, the mixed signals from weekly RSI and KST indicators advise a measured approach, as short-term volatility may persist.

Investor Takeaways and Outlook

For investors, the recent technical upgrades in Natco Pharma offer a cautiously optimistic outlook. The bullish MACD, moving averages, and Bollinger Bands across daily, weekly, and monthly charts provide a strong foundation for potential price appreciation. The stock’s outperformance relative to the Sensex over short and medium terms further supports this view.

Nevertheless, the bearish weekly RSI and monthly KST indicators highlight the importance of monitoring momentum shifts closely. These mixed signals suggest that while the trend is positive, intermittent pullbacks or consolidation phases may occur. Investors should consider these factors alongside fundamental developments and sector trends before making allocation decisions.

Given the Hold Mojo Grade and a moderate Mojo Score of 64.0, Natco Pharma currently represents a balanced risk-reward proposition. It is well-positioned to benefit from sector tailwinds and technical momentum but may require confirmation of sustained strength before being rated a strong buy.

Overall, Natco Pharma’s technical parameter changes mark a pivotal moment in its market journey, signalling a transition from sideways movement to a more bullish phase. This shift, supported by multiple technical indicators and relative strength metrics, warrants close attention from market participants seeking exposure to the Pharmaceuticals & Biotechnology sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →